Compare NKX & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NKX | REPL |
|---|---|---|
| Founded | 2002 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 645.5M | 721.7M |
| IPO Year | N/A | 2018 |
| Metric | NKX | REPL |
|---|---|---|
| Price | $12.45 | $10.03 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | 109.3K | ★ 1.7M |
| Earning Date | 01-01-0001 | 11-06-2025 |
| Dividend Yield | ★ 4.37% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.78 | $2.68 |
| 52 Week High | $12.00 | $14.80 |
| Indicator | NKX | REPL |
|---|---|---|
| Relative Strength Index (RSI) | 26.51 | 57.76 |
| Support Level | $12.70 | $9.63 |
| Resistance Level | $12.80 | $10.29 |
| Average True Range (ATR) | 0.07 | 0.59 |
| MACD | -0.03 | -0.10 |
| Stochastic Oscillator | 2.63 | 35.68 |
Nuveen California AMT-Free Quality Municipal Income Fund is a closed-end fixed income mutual fund. The Fund's primary investment objective is current income exempt from both regular federal income taxes and Arizona individual income taxes and to enhance portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds that the Fund's investment adviser believes are underrated or undervalued or that represent municipal market sectors that are undervalued. It invests across sectors such as healthcare, utilities, transportation, and housing.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.